BioLife Solutions, Inc. $BLFS Shares Bought by Public Sector Pension Investment Board

Key Points

• The Public Sector Pension Investment Board increased its stake in BioLife Solutions, Inc. by 27.2% in Q1, now owning approximately 0.24% of the company valued at $2.62 million.
• Several analysts have provided positive ratings for BioLife Solutions, with a consensus rating of "Buy" and a target price of $31.29.
• BioLife Solutions reported a loss per share of ($0.33) in its last earnings, missing the consensus estimate, despite achieving revenue of $25.42 million.

Public Sector Pension Investment Board lifted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 27.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 114,696 shares of the medical equipment provider's stock after acquiring an additional 24,548 shares during the period. Public Sector Pension Investment Board owned 0.24% of BioLife Solutions worth $2,620,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions during the fourth quarter valued at approximately $31,000. US Bancorp DE boosted its stake in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,528 shares during the last quarter. GAMMA Investing LLC boosted its stake in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after buying an additional 663 shares during the last quarter. Avantax Advisory Services Inc. boosted its stake in BioLife Solutions by 16.0% during the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock valued at $207,000 after buying an additional 1,250 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new position in BioLife Solutions during the fourth quarter valued at approximately $254,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insiders Place Their Bets

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of BioLife Solutions stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the completion of the sale, the insider owned 7,707,165 shares of the company's stock, valued at approximately $183,430,527. The trade was a 11.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 2,008,831 shares of company stock worth $47,499,658. 2.20% of the stock is owned by insiders.

BioLife Solutions Stock Performance

BLFS traded up $0.83 during trading on Friday, hitting $25.91. 652,188 shares of the stock were exchanged, compared to its average volume of 557,506. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.55. The firm has a 50 day simple moving average of $22.32 and a 200 day simple moving average of $23.41. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -215.90 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The company had revenue of $25.42 million during the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Stephens assumed coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price objective for the company. Wall Street Zen lowered BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. Finally, HC Wainwright reissued a "buy" rating and set a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of "Buy" and an average price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.